EP2991650A4 - Methods for the treatment of cancer - Google Patents

Methods for the treatment of cancer Download PDF

Info

Publication number
EP2991650A4
EP2991650A4 EP14791444.4A EP14791444A EP2991650A4 EP 2991650 A4 EP2991650 A4 EP 2991650A4 EP 14791444 A EP14791444 A EP 14791444A EP 2991650 A4 EP2991650 A4 EP 2991650A4
Authority
EP
European Patent Office
Prior art keywords
cancer
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14791444.4A
Other languages
German (de)
French (fr)
Other versions
EP2991650A1 (en
Inventor
Robert Goodenow
Peter Ordentlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndax Pharmaceuticals Inc
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of EP2991650A1 publication Critical patent/EP2991650A1/en
Publication of EP2991650A4 publication Critical patent/EP2991650A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
EP14791444.4A 2013-05-03 2014-05-02 Methods for the treatment of cancer Withdrawn EP2991650A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
EP2991650A1 EP2991650A1 (en) 2016-03-09
EP2991650A4 true EP2991650A4 (en) 2017-01-25

Family

ID=51843995

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14791444.4A Withdrawn EP2991650A4 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Country Status (6)

Country Link
EP (1) EP2991650A4 (en)
JP (2) JP2016522188A (en)
KR (1) KR102337598B1 (en)
CN (1) CN105492007A (en)
HK (1) HK1223547A1 (en)
WO (1) WO2014179738A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180353602A1 (en) * 2015-06-29 2018-12-13 Syndax Pharmaceuticals, Inc. Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
JP2019524748A (en) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
KR20240042244A (en) * 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. Combination therapies
KR20210029190A (en) * 2018-06-06 2021-03-15 아레나 파마슈티칼스, 인크. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861094A4 (en) * 2005-03-11 2014-06-11 Univ Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2658170A1 (en) * 2006-07-11 2008-01-17 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
BRPI0909818A2 (en) * 2008-03-07 2015-10-06 Pfizer methods, dosage forms and kit for administering ziprasidone without food
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
EA201201474A1 (en) * 2011-09-02 2013-08-30 Синдэкс Фармасьютикалс, Инк. METHODS OF TREATMENT BREAST CANCER

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT01594398 on 2012_07_31: ClinicalTrials.gov Archive", 31 July 2012 (2012-07-31), XP055323902, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT01594398/2012_07_31> [retrieved on 20161129] *
L. GORE ET AL: "A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas", CLINICAL CANCER RESEARCH, vol. 14, no. 14, 15 July 2008 (2008-07-15), US, pages 4517 - 4525, XP055323917, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1461 *
NILOFER AZAD ET AL: "The future of epigenetic therapy in solid tumours-lessons from the past", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 10, no. 5, 2 April 2013 (2013-04-02), NY, US, pages 256 - 266, XP055324023, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2013.42 *
S. KUMMAR ET AL: "Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies", CLINICAL CANCER RESEARCH, vol. 13, no. 18, 15 September 2007 (2007-09-15), US, pages 5411 - 5417, XP055323928, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-0791 *
See also references of WO2014179738A1 *

Also Published As

Publication number Publication date
JP2019112416A (en) 2019-07-11
JP6860949B2 (en) 2021-04-21
KR20160003182A (en) 2016-01-08
KR102337598B1 (en) 2021-12-10
WO2014179738A1 (en) 2014-11-06
CN105492007A (en) 2016-04-13
HK1223547A1 (en) 2017-08-04
JP2016522188A (en) 2016-07-28
EP2991650A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
EP3027192A4 (en) Methods for the treatment of solid tumors
EP3076977A4 (en) Combination therapy for treating cancer
EP2964028A4 (en) Compounds for treatment of cancer
EP3033079A4 (en) Methods for the treatment of her2 amplified cancer
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
PL3033086T3 (en) Combination therapy for the treatment of cancer
EP2968254A4 (en) Methods of treating lung cancer
EP3057594A4 (en) Method of treating cancer
EP2994148B8 (en) Cancer therapy
EP3007756A4 (en) Catheter-assisted tumor treatment
EP3004396A4 (en) Methods and compositions for the treatment of cancer
PT3089749T (en) Combined preparations for the treatment of cancer
EP3008212A4 (en) Methods of treatment of cancer
HK1222548A1 (en) Pharmaceutical combinations for the treatment of cancer
EP3074040A4 (en) Method of treating cancer
HK1219737A1 (en) Novel compounds for the treatment of cancer
EP3057593A4 (en) Treatment for pancreatic cancer
EP3044593A4 (en) Cancer therapy
EP3011013A4 (en) Methods for treatment of ovarian cancer
EP3003489A4 (en) Cytotoxic agents for the treatment of cancer
EP3252171B8 (en) Methods of treating cancer
HK1223547A1 (en) Methods for the treatment of cancer
EP3089745A4 (en) Compounds, compositions, and methods for the treatment of cancers
HK1221681A1 (en) Methods for the treatment of neurodegeneration
EP3049078A4 (en) Treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20161219BHEP

Ipc: A61K 31/5685 20060101ALI20161219BHEP

Ipc: A61K 31/4406 20060101AFI20161219BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20190111